title: Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men.
abstract: Prostate cancer (PCa) is the most common solid neoplasm diagnosed in developed countries. Nerve-sparing radical prostatectomy (NS-RP) has been widely accepted as the best choice treatment for localised PCa. However, erectile dysfunction (ED) and urinary incontinence are commonly observed after NS-RP. Using meta-analysis, we examined if phosphodiesterase type 5 inhibitors (PDE5-Is) could improve the symptoms of ED in patients undergoing NS-RP. This review contained seven randomised placebo-controlled trials with a total of 2,655 male patients. Patients in PDE5-Is group showed significant improvement in the International Index of Erectile Function-Erectile Function domain score (IIEF-EF), Global Assessment Questionnaire (GAQ), Sexual Encounter Profile question 2 (SEP-2) and SEP-3. Although the incidence of treatment-emergent adverse events (TEAEs) were high in both groups (56.44% vs. 40.63%), the safety profile were acceptable, with low incidence of discontinuation rate due to adverse events. Therefore, PDE5-Is are recommended for the treatment of post-NS-RP ED. Patients should be informed of possible adverse events.
authors: 1] Department of Urology, West china hospital, Sichuan University, Chengdu, China [2].
authors: Jinhong
authors: J
authors: Li
authors: 1] Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China [2].
authors: Qingquan
authors: Q
authors: Shi
authors: Department of Urology, West china hospital, Sichuan University, Chengdu, China.
authors: Chunxiao
authors: C
authors: Pu
authors: Department of Urology, West china hospital, Sichuan University, Chengdu, China.
authors: Yin
authors: Y
authors: Tang
authors: Department of Urology, West china hospital, Sichuan University, Chengdu, China.
authors: Yunjin
authors: Y
authors: Bai
authors: Department of Urology, West china hospital, Sichuan University, Chengdu, China.
authors: Haichao
authors: H
authors: Yuan
authors: Department of Urology, West china hospital, Sichuan University, Chengdu, China.
authors: Xiang
authors: X
authors: Li
authors: Department of Urology, West china hospital, Sichuan University, Chengdu, China.
authors: Qiang
authors: Q
authors: Dong
authors: Department of Urology, West china hospital, Sichuan University, Chengdu, China.
authors: Qiang
authors: Q
authors: Wei
authors: Department of Urology, West china hospital, Sichuan University, Chengdu, China.
authors: Jiuhong
authors: J
authors: Yuan
authors: Department of Urology, West china hospital, Sichuan University, Chengdu, China.
authors: Ping
authors: P
authors: Han
mesh_terms: D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D011379:Prognosis; D011468:Prostatectomy / Q000009:adverse effects*; D011471:Prostatic Neoplasms / Q000601:surgery*; D016032:Randomized Controlled Trials as Topic
chemical_list: D058986:Phosphodiesterase 5 Inhibitors